DAHANCA 19: The Importance of the EGFr-inhibitor Zalutumumab for the Outcome After Curative Radiotherapy for HNSCC
Status:
Completed
Trial end date:
2016-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether the addition of the fully human EGFr
antibody zalutumumab to primary curative radiotherapy increases locoregional control in
Squamous Cell Carcinomas of the Head and Neck.